Aug 20, 2025
Indivior to Participate in Upcoming Investor Events
Sep 30, 2020
Indivior Calls for Widespread Commitment to Tackling Stigma in Patients with Opioid Use Disorder
Sep 22, 2020
Indivior Underscores Commitment to Putting Patients First during this Recovery Month
Jun 30, 2020
US Government Agreement With Former CEO
Apr 22, 2020
Global Opium (Opioid) Addiction Therapeutic Landscape: 2020 Pipeline Guide
Mar 23, 2020
One-Year Outcomes of Real-World RECOVER(TM) Study Published in Journal of Addiction Medicine
Nov 11, 2019
Indivior Launches National Campaign Informing People of an Additional Treatment for Opioid Use Disorder (OUD) and to Let People with OUD Know That They Can "Keep Moving Towards Recovery"
Oct 31, 2019
Indivior 2019 Third Quarter and Nine Months Results Now Available; Conference Call With Leadership Today
Sep 26, 2019
Announcement of National Institutes of Health (NIH) Grant Award through the NIH Helping to End Addiction Long-term (HEAL) Initiative
Jul 31, 2019
Indivior First Half 2019 Results Now Available; Conference Call With Leadership Today
Jul 11, 2019
Indivior Raises FY 2019 Net Revenue and Net Income Guidance; Cash at H1 2019 Expected to be Approximately $985m
Jun 17, 2019
New Data from the RECOVER(TM) Study Reports on Abstinence, Drug Craving and Psychosocial Outcomes in People with Opioid Use Disorder following Transition from a Clinical Trial to the Real-World Setting
May 07, 2019
Bernstein Liebhard LLP Announces That Approximately Seven Weeks Remain To Make A Motion For Lead Plaintiff In A Class Against Indivior PLC
May 02, 2019
Indivior First Quarter 2019 Results Now Available; Conference Call With Leadership Today
Apr 25, 2019
Johnson Fistel Announces Class Action Suit against Indivior PLC (INVVY); Encourages Investors to Contact the Firm for Additional Information
Apr 06, 2019
Indivior Announces New Study Data in Patients with Moderate to Severe Opioid Use Disorder (OUD) at the 50th ASAM Annual Conference
Apr 05, 2019
Indivior's RECOVER(TM) Study Finds Three-quarters of Patients with Moderate to Severe Opioid Use Disorder Who Received 12 monthly Injections of SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection were Abstinent from Illicit Opioids One Year Later
Mar 07, 2019
The Journal of Addiction Medicine Publishes Patient-centered Outcomes from the Phase 3 Study of SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection in Patients with Moderate to Severe Opioid Use Disorder (OUD)
Feb 22, 2019
Mylan Launches Generic Suboxone® Sublingual Film to Treat Opioid Dependence
Feb 20, 2019
Alvogen Launches Generic Equivalent to Suboxone® (Buprenorphine/Naloxone) Sublingual Film